BUSULFANUM
Retinoblastoma
Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Dormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Retinoblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivestim Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
SUBA-ITRACONAZOLE COMPONENT ITRACONAZOLE Samsung Medical Center | Phase 4 | BB |
Thiotepa Masonic Cancer Center, University of Minnesota | Phase 2 | BB |
Cyclophosphamide Seattle Children's Hospital | Phase 2 | BB |
NOGITECAN Emory University | Phase 2 | BB |
View all 28 →
Same molecule, other indications
BUSULFANUM is also rated in:
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →